タチバナ　ヒデカズ   Hidekazu Tachibana   橘　秀和    所属   医学部 医学科（東京女子医科大学病院）    職種   非常勤講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy.
掲載誌名	正式名：Anticancer research 略　 称：Anticancer Res ISSNコード：02507005/17917530
掲載区分	国外
巻・号・頁	41(3),pp.1607-1614
著者・共著者	ISHIYAMA Yudai†, KONDO Tsunenori*, NEMOTO Yuki, KOBARI Yuki, ISHIHARA Hiroki, TACHIBANA Hidekazu, YOSHIDA Kazuhiko, HASHIMOTO Yasunobu, TAKAGI Toshio, IIZUKA Junpei, TANABE Kazunari
発行年月	2021/03
概要	BACKGROUND/AIM:We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab.PATIENTS AND METHODS:Sixty-five patients were retrospectively enrolled and classified as low (<40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated.RESULTS:In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group.CONCLUSION:PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab.
DOI	10.21873/anticanres.14922
PMID	33788756